All sponsors

Supernus Pharmaceuticals, Inc.

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS6
PHASE 3 / 2-31
RECRUITING3
READOUTS ≤12 MONTHS4
READOUT SLIPPED >6 MO60%

Delay Index: of 5 active trials registered more than a year ago, 3 have moved their primary completion (readout) date by more than 6 months since first registration (median +10.0 months). See all sponsors →

Open Supernus Pharmaceuticals, Inc. on the live radar map →
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
SPN-812
NCT02736656
P3Active, not recruitingAttention-Deficit/Hyperactivity Disorder14002026-12 (+92 mo)
FIAS
NCT03474770
P1/2Active, not recruitingFocal Impaired Awareness Seizures162026-12-30
SPN-821 2400 mg
NCT07226661
P2RecruitingMajor Depressive Disorder (MDD)2302026-12-31
SPN-817
NCT06798896
P2RecruitingFocal Onset Seizures2162027-08 (+10 mo)
SPN-817
NCT05518578
P2RecruitingEpilepsy; Seizures, Epileptic602027-12-31 (+39 mo)
SPN-817
NCT07141329
P2Enrolling by invitationFocal Onset Seizures1002027-12-31